Cargando…
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT
The clinical successes of immune checkpoint blockade have invigorated efforts to activate T cell-mediated responses against cancer. Targeting members of the PVR family, consisting of inhibitory receptors TIGIT, CD96, and CD112R, has been an active area of clinical investigation. In this study, the b...
Autores principales: | Diong, SJ J., Jashnani, Aarti, Drake, Andrew W., Bee, Christine, Findeisen, Felix, Dollinger, Gavin, Wang, Feng, Rajpal, Arvind, Strop, Pavel, Lee, Peter S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486284/ https://www.ncbi.nlm.nih.gov/pubmed/37675979 http://dx.doi.org/10.1080/19420862.2023.2253788 |
Ejemplares similares
-
Antibody blockade of CD96 by distinct molecular mechanisms
por: Lee, Peter S., et al.
Publicado: (2021) -
Impact of Drug Conjugation on Thermal and Metabolic
Stabilities of Aglycosylated and N-Glycosylated
Antibodies
por: Yamazoe, Sayumi, et al.
Publicado: (2022) -
Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020) -
Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT
por: Zhou, Xiaowen, et al.
Publicado: (2021) -
Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
por: Zhou, Xiuman, et al.
Publicado: (2020)